Sign in
Taking people in United StatesNo phase

Testing the FastWire device for fully blocked leg arteries

Tests the FastWire System for crossing fully blocked arteries in adults' legs.

Key facts

Who runs it
Versono Medical Ltd
Where
Chattanooga, Cocoa, Davenport, Dearborn, Gray, and Wilmington, United StatesSee the 6 sites
Trial code
Registry title
FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW
Status
Recruiting
People taking part
65 people, planned
Started
5 Nov 2024
Expected to end
Nov 2026
Type of study
Interventional
Treatments tested
  • FastWire System - Peripheral
Record updated
20 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a fully blocked leg artery (chronic total occlusion) who will have a procedure using the FastWire System to cross the blockage.

Age
18 Years to 85 Years
Sex
All
Disease stage
Severe leg pain when walking (Rutherford category 3), or chronic limb-threatening ischaemia (Rutherford category 4 or 5). The blockage is new (de novo), 100% blocked, and below the start of the superficial femoral artery, above or below the knee. If there are several blockages, their total length is less than 40 cm (16 in). For blockages below the knee, at least one open run-off vessel (<50% stenosis) is needed.
Earlier treatment
No earlier bypass that includes the target vessel. No earlier angioplasty or stenting in the target blockage. No clot-dissolving (thrombolytic) therapy in the last two weeks.

Main reasons for not taking part

  • Life expectancy of less than 12 months, or pregnant or breastfeeding.
  • Heart attack or stroke in the 2 months before the procedure, or unstable heart disease.
  • Bleeding or clotting problems, or platelet count < 50,000/μL.
  • eGFR of less than 30 ml/min or creatine level >2.5mg/ml.
  • Allergy to nickel, titanium or contrast medium, or active infection.

The registry criteria, word for word

Show all 29 criteriaShow less

Who cannot take part

  • Myocardial infarction or stroke in two months prior to the index procedure
  • Patients who have received any thrombolytic therapy in the last two weeks
  • Subject participating in another study involving an investigational drug or device
  • Patient has surgery or vascular intervention planned within 30 days of the index procedure
  • Patient has had a previous peripheral bypass that includes the target vessel
  • Patient has had a previous intervention in the target CTO (angioplasty, stenting) including previous attempt at time of index procedure
  • Has perforation, dissection, or other injury of the access site or index vessel requiring stenting or surgical intervention prior to attempting crossing of the target lesion with the FastWire System
  • Known, unstable coronary artery disease or other, uncontrolled comorbidity
  • Evidence of active infection, including but not limited to the target limb
  • History of severe allergy or contraindication, to contrast medium or other medications used during or after endovascular therapy
  • Patient tests positive for coronavirus disease (COVID-2019), as per site standard practice
  • Estimated Glomerular Filtration Rate (eGFR) of less than 30 ml/min or creatine level >2.5mg/ml
  • Platelet count < 50,000/μL; Angiographic Exclusion Criteria; Unless otherwise specified, the Investigator performing the procedure bases angiographic exclusion on a visual determination of qualification imaging taken at the time of the procedure. Subject is excluded if ANY of the following angiographic exclusion criteria is met:
  • Females who are pregnant or lactating (urine test for women of childbearing age)
  • Subjects who meet any of the following criteria are not eligible for this clinical investigation:
  • Life expectancy of less than 12 months
  • Any known haemorrhagic or coagulation deficiency
  • Known sensitivity to nickel, titanium, or their alloys
  • Current use of cocaine or other substances of abuse
  • For below-the-knee CTOs, a target limb without at least one patent (<50% stenosis) run-off vessel confirmed by angiography or magnetic resonance angiography at the time of the procedure
  • Has an acute or sub-acute intraluminal thrombus within the target vessel
  • Aneurysm distal to puncture access site at least twice the reference vessel diameter, located in the index vessel, abdominal aorta, iliac, or popliteal

Other criteria

  • General Inclusion Criteria: Subjects who meet all the following criteria are eligible for this clinical investigation:
  • The patient signed and dated an Informed Consent Form
  • Aged between 18 years and 85 years (inclusive)
  • Severe claudication assessed as Rutherford category 3 or CLTI assessed as Rutherford category 4 or 5 LEAD; Angiographic Inclusion Criteria; Unless otherwise specified, the Investigator performing the procedure bases angiographic inclusion on the visual determination of qualification imaging taken at the time of the procedure. Subject must meet ALL the following angiographic inclusion criteria:
  • Angiographic confirmation at the time of the procedure of a de novo CTO below the origin of the superficial femoral artery (SFA) including above the knee or below the knee. (Note: Multilevel CTOs are included as long as the total length from the beginning of the most proximal total occlusion to the end of the most distal total occlusion is less than 40 cm.)
  • 100% stenosis by a visual estimate of angiography at the time of procedure
  • For below-the-knee CTOs, the target limb shall have at least one patent (<50% stenosis) run-off vessel confirmed by angiography or magnetic resonance angiography at the time of the procedure

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

This trial is currently available in United States.

  • Vascular Institute of ChattanoogaChattanooga, United StatesContact: Lacey WeeksTaking people
  • Vascular & Embolization SpecialistsCocoa, United StatesContact: Brandon GalavizTaking people
  • Vascular Institute of the MidwestDavenport, United StatesContact: Dr. Eric Dippel, M.D.Taking people
  • Dearborn CardiologyDearborn, United StatesContact: Sam RengadeTaking people
  • Cardiovascular Institute of the South-ASCGray, United StatesContact: Darla Patrick, RN, CCRCTaking people
  • Endovascular ConsultantsWilmington, United StatesContact: Jas KaurTaking people

About the trial

What the trial wants to find out

This study is to assess the safety and efficacy of the FastWire System. It is intended to assess that the FastWire System can facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions (CTOs)

The group in the trial

  • FastWire System - PeripheralTreatment being tested

    This study is to assess the safety and efficacy of the FastWire System. It is intended to assess that the FastWire System can facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions (CTOs).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pivotal, Single-arm, Multi-centre, Prospective Clinical Investigation to Assess the Efficacy and Safety of the FastWire REvascularisation of Extremities, (For LOWer Limbs) (FREEFLOW).
Plain-language title
Testing the FastWire device for fully blocked leg arteriesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06492733, who can take part
Record updated
20 August 2026